• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Case 4–2015
ATRIAL FIBRILLATION (AF) is the most common cardiac arrhythmia in the world and is estimated to affect more than 3 million people in the United States, with a projected increase to more than 5 million people in the US by the year 2050.1 AF is an independent risk factor for stroke and is associated with a four- to five-fold increased risk of embolic stroke compared with those individuals without AF. Oral anticoagulation therapy with warfarin or other agents (dabigatran, apixaban) significantly reduces the risk of stroke in this population; however, anticoagulation carries inherent risks.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 18, 2015 Category: Anesthesiology Authors: Megan J. Lanigan, Mark A. Chaney, Sandeep Nathan, Atman P. Shah, Andrew J. Feider Tags: Case Conference Source Type: research

Left Atrial Appendage Closure With the Watchman™ Device
Conclusions Left atrial appendage closure with the WatchmanTM device is feasible and may be a good alternative therapy for stroke prevention in patients with atrial fibrillation and restrictions for anticoagulation.
Source: Revista Brasileira de Cardiologia Invasiva - November 26, 2014 Category: Cardiology Source Type: research

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (P5.002)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (I2-2.003)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: New Antithrombotic Agents for Stroke Prevention Data Blitz Presentations Source Type: research

Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To assess evidence regarding periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review with practice recommendations. Results and recommendations: Clinicians managing antithrombotic medications periprocedurally must weigh bleeding risks from drug continuation against thromboembolic risks from discontinuation. Stroke patients undergoing dental procedures should routinely continue aspirin (Level A). Stroke patients underg...
Source: Neurology - May 27, 2013 Category: Neurology Authors: Armstrong, M. J., Gronseth, G., Anderson, D. C., Biller, J., Cucchiara, B., Dafer, R., Goldstein, L. B., Schneck, M., Messe, S. R. Tags: Ultrasound, All Medical/Systemic disease, All Neuro-ophthalmology, All Cerebrovascular disease/Stroke, All Trauma SPECIAL ARTICLE Source Type: research

Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include direct Factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. In elective surgery, discontinuing their use is important, but renal function must also be considered because elimination is highly dependent on renal elimination. If bleeding occurs in patients who have received these agents, common principles of bleeding management as with an...
Source: Anesthesiology - April 23, 2013 Category: Anesthesiology Tags: Education: Review Article Source Type: research

Anesthesia-Based Evaluation of Outcomes of Lower-Extremity Vascular Bypass Procedures
Conclusion: These results provide no evidence to support the systematic avoidance of general anesthesia for lower-extremity bypass procedures. These data suggest that anesthetic choice should be governed by local expertise and practice patterns.
Source: Annals of Vascular Surgery - September 3, 2012 Category: Surgery Authors: Racheed J. Ghanami, Justin Hurie, Jeanette S. Andrews, Robert N. Harrington, Matthew A. Corriere, Philip P. Goodney, Kimberley J. Hansen, Matthew S. Edwards Tags: Clinical Research Source Type: research

Pages: 1  2  3